Hepatology Communications (Nov 2018)

Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis

  • Mark R. Deneau,
  • Cara Mack,
  • Reham Abdou,
  • Mansi Amin,
  • Achiya Amir,
  • Marcus Auth,
  • Fateh Bazerbachi,
  • Anne Marie Broderick,
  • Albert Chan,
  • Matthew DiGuglielmo,
  • Wael El‐Matary,
  • Mounif El‐Youssef,
  • Federica Ferrari,
  • Katryn N. Furuya,
  • Frederic Gottrand,
  • Nitika Gupta,
  • Matjaž Homan,
  • M.K. Jensen,
  • Binita M. Kamath,
  • Kyung Mo Kim,
  • Kaija‐Leena Kolho,
  • Anastasia Konidari,
  • Bart Koot,
  • Raffaele Iorio,
  • Mercedes Martinez,
  • Parvathi Mohan,
  • Sirish Palle,
  • Alexandra Papadopoulou,
  • Amanda Ricciuto,
  • Lawrence Saubermann,
  • Pushpa Sathya,
  • Eyal Shteyer,
  • Vratislav Smolka,
  • Atsushi Tanaka,
  • Pamela L. Valentino,
  • Raghu Varier,
  • Veena Venkat,
  • Bernadette Vitola,
  • Miriam B. Vos,
  • Marek Woynarowski,
  • Jason Yap,
  • Tamir Miloh

DOI
https://doi.org/10.1002/hep4.1251
Journal volume & issue
Vol. 2, no. 11
pp. 1369 – 1378

Abstract

Read online

Adverse clinical events in primary sclerosing cholangitis (PSC) happen too slowly to capture during clinical trials. Surrogate endpoints are needed, but no such validated endpoints exist for children with PSC. We evaluated the association between gamma glutamyltransferase (GGT) reduction and long‐term outcomes in pediatric PSC patients. We evaluated GGT normalization ( 75% versus 75% by 1 year after PSC diagnosis predicts favorable 5‐year outcomes in children. GGT has promise as a potential surrogate endpoint in future clinical trials for pediatric PSC.